skip to Main Content

A New Horizon in Cancer Care: Liquid Biopsy

Newsfeed image, light gray text on dark gray background
Thanks to innovations in liquid biopsy platforms within the past decade, the oncology world is witnessing the transformation of precision medicine in cancer care. The first FDA approval of a liquid biopsy test was the CellSearchCTC enumeration platform in 2013, which is centered on the detection of circulating tumor cells (CTC) in blood.1 In 2016, the FDA approved the first circulating tumor DNA (ctDNA) blood test, cobas EGFR Mutation Test v2, to detect EGFR gene mutations in patients with non–small cell lung cancer (NSCLC).

In 2020, th e FDA approved 2 additional comprehensive genomic profiling liquid biopsy tests, Guardant360 CDx and FoundationOne Liquid CDx, which both utilize next-generation sequencing technology to detect tumor genomic alterations in cell-free ctDNA in blood.3,4 Although Guardant360 CDx can detect changes in more than 60 different genes that are relevant in solid tumors, FoundationOne Liquid CDx can identify mutations or alterations in 300 or more genes. Read more . . . 

Back To Top